Introduction {#s1}
============

The ability to recover from sleep loss is critical for preserving cognitive processes and executive functioning ([@bib24]; [@bib29]; [@bib31]). The mechanisms that are responsible for the recovery from sleep loss are not well understood. Genetic deletion of the circadian transcription factor *Bmal1* (brain and muscle ARNT-like factor; gene symbol *Arntl*) in mice completely ablates circadian clock function ([@bib6]) and has effects on sleep that include: increased total sleep amount, increased non-rapid eye movement (NREM) sleep intensity and reduced ability to recover from sleep loss ([@bib18]). Because *Bmal1* whole-body deletion causes a broad range of physical abnormalities (e.g. reduced locomotor activity, joint abnormalities, reduced lifespan; [@bib7]; [@bib17]), we sought to isolate sleep phenotypes from the potential effects of other phenotypes using tissue-specific *Bmal1* rescue and knockout models.

We first attempted to rescue electroencephalographic (EEG) sleep-phenotypes in *Bmal1* knockout mice by restoring functional *Bmal1* expression selectively in brain. To do this, we used a transgenic model that rescues *Bmal1* expression in the brain of *Bmal1* whole-body KO's, thus restoring circadian behavior (*Scg2::tTa; tetO::Bmal1-HA;* [@bib25]). Surprisingly, transgenic *Bmal1* expression in the brain (i.e., brain rescued) did not restore NREM sleep-amount---one of the most prominent sleep changes in whole-body *Bmal1* knockouts ([Figure 1A,B](#fig1){ref-type="fig"}). Since circadian rhythms of locomotor activity are restored in this model ([@bib25]), our finding suggests that the sleep disturbances in *Bmal1* knockout mice are not exclusively the result of disrupted circadian behavior. More importantly, the results show that *Bmal1* expression in brain does not restore normal sleep amounts in *Bmal1* knockout mice, suggesting that expression in other tissues may be important.10.7554/eLife.26557.003Figure 1.Rescuing *Bmal1* in skeletal muscle restores daily non-rapid eye movement (NREM) sleep amount.24 hr electroencephalographic recordings were conducted in undisturbed mice listed in the legend. The 24 hr pattern of NREM and REM sleep are shown in A. Whole-body knockout of *Bmal1* significantly increased NREM sleep when compared to WT controls (B, ANOVA F~(2,27)~=11.3, p=0.005; p\<0.001, posthoc Tukey's test). Rescuing *Bmal1*in the brain of knockouts did not restore NREM sleep to WT levels (B, p=0.001 vs. WT; Tukey's test); however, the effect of *Bmal1* knockout was reversed when *Bmal1* was rescued in the skeletal muscle (C, ANOVA F~(2,31)~=9.9, p\<0.001; p=0.88 vs. WT, p\<0.001 vs. KO, Tukey's test). No differences were found in REM sleep or NREM slow-wave activity. Knockout animals are replotted in B and C to aid in comparison. KO mice were offspring from independent crosses of heterozygous *Bmal1* KO's. Representative electroencephalographic recordings are displayed in D. Grey boxes indicate the active/dark period. Bars and points represent mean ± s.e.m. \*, p\<0.05. WT (brain) n = 11, knockout n = 12, muscle rescue n = 5, brain rescue n = 4, WT (muscle) n = 16.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.003](10.7554/eLife.26557.003)10.7554/eLife.26557.004Figure 1---figure supplement 1.*Bmal1-HA* is not detectable in the Brains of *Acta1::Bmal1-HA* mice.Fifty micrograms of proteins extracted from either an entire brain hemisphere or skeletal muscle (gastrocnemius) were subjected to western blotting with the indicated antibodies.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.004](10.7554/eLife.26557.004)

To begin this investigation of other tissues, we chose mice harboring a transgene that restores *Bmal1* specifically in skeletal muscle, but does not restore circadian behavior (i.e., muscle rescued; *Acta1::Bmal1-HA*). This model rescues several muscle-related phenotypes despite non-cycling BMAL1 levels ([@bib25]). To our surprise, although REM sleep was unaffected ([Figure 1B and C](#fig1){ref-type="fig"}), we found that restoring *Bmal1* in skeletal muscle completely restored NREM sleep amount to wild-type levels in otherwise *Bmal1*-deficient mice ([Figure 1C](#fig1){ref-type="fig"}). We also assessed whether *Bmal1* function in the skeletal muscle altered sleep intensity by measuring NREM slow wave activity (SWA, 0.5--4 Hz; [@bib2]; [@bib12]). In our hands, NREM SWA was not altered in *Bmal1* knockout mice; similarly, NREM SWA was not significantly altered by rescuing BMAL1 in brain or muscle ([Figure 1B and C](#fig1){ref-type="fig"}). These experiments demonstrate that restoring *Bmal1* in the skeletal muscle of otherwise *Bmal1*-deficient mice is sufficient to restore normal NREM sleep amount, independently of *Bmal1* expression in the brain. The diurnal rhythm in sleep amount, however, is not restored ([Figure 1A](#fig1){ref-type="fig"}).

To investigate the effect of *Bmal1* function on recovery from sleep loss, we subjected the *Bmal1* mouse lines to 6 hr of forced wakefulness and monitored sleep EEG's during recovery ([Figure 2A](#fig2){ref-type="fig"}). The amount and type of recovery sleep observed in response to forced wakefulness is commonly used to assess changes in sleep homeostasis (i.e., sleep drive)---this recovery is typically characterized by increased sleep amount and increased SWA ([@bib13]). Whole-body KO of *Bmal1* did not affect NREM recovery-sleep amount ([Figure 2A,B](#fig2){ref-type="fig"}), but did significantly prevent increased NREM-SWA ([Figure 2C,D](#fig2){ref-type="fig"}). Rescue of *Bmal1* in either brain- or muscle-rescued mice reduced NREM recovery-sleep following forced wakefulness ([Figure 2A,B](#fig2){ref-type="fig"}), a finding that indicates *Bmal1* restoration in either tissue reduces sleep drive following forced wakefulness. Notably, NREM SWA in whole-body KO mice was rescued by restoring *Bmal1* in skeletal muscle, but not brain ([Figure 2A,B](#fig2){ref-type="fig"}). These findings demonstrate that restoring *Bmal1* in the skeletal muscle of *Bmal1*-deficient mice is sufficient to restore normal SWA following sleep loss.10.7554/eLife.26557.005Figure 2.Rescuing *Bmal1* in skeletal muscle or brain reduces the amount of NREM sleep recovered after forced wakefulness.Continuous sleep recordings during 18 hr of recovery sleep were obtained from the mice in [Figure 1](#fig1){ref-type="fig"} after 6 hr of forced wakefulness (**A**; yellow double arrow = forced wakefulness). The total NREM recovery sleep during this 18 hr period in brain-rescued and muscle-rescued mice was reduced when compared to WT mice (**B**, ANOVA brain rescued, F~(2,28)~=6.47, p=0.005, p=0.004 Tukey's; ANOVA muscle rescued, F~(2,30)~=5.45, p=0.01 Tukey's). Values in A and B represent sleep time gained after forced wakefulness (calculated using the corresponding interval during undisturbed sleep) as a percentage of total sleep lost (mean ± s.e.m.). The distribution of EEG power during NREM sleep for representative animals from each genotype is shown in (panel **C**). Slow wave activity (highlighted area) represents power in the 0.5 to 4 Hz frequency band. NREM slow wave activity was reduced in knockout mice following forced wakefulness---compared to WT mice (**D**, % change over corresponding baseline; p\<0.01, Tukey's test). This reduction in slow wave activity was absent when *Bmal1* was rescued in the skeletal muscle (**D**). Knockout animals in B and D are replicated between graphs to aid in comparison. \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.005](10.7554/eLife.26557.005)10.7554/eLife.26557.006Figure 2---figure supplement 1.Rescuing *Bmal1* in skeletal muscle or brain reduces the amount of NREM sleep recovered after forced wakefulness.Continuous sleep recordings during 18 hr of recovery sleep were obtained from the mice in [Figure 1](#fig1){ref-type="fig"} after 6 hr of forced wakefulness (squares, dotted line). NREM sleep amount is plotted as a percentage of total sleep for 2 hr bins across 24 h days. Each plot includes baseline sleep (circles, solid line) on the preceding day for comparison. (yellow double arrow = forced wakefulness). Points represent mean ± s.e.m. \*p\<0.05 Tukey's. Statistics are not reported for the first 6 hr (sleep deprivation period).**DOI:** [http://dx.doi.org/10.7554/eLife.26557.006](10.7554/eLife.26557.006)

Our results indicate that the rescue of *Bmal1* in skeletal muscle is sufficient to restore both NREM sleep amount and the SWA recovery-responses to lost sleep. We next sought to determine if *Bmal1* in skeletal muscle was necessary for the effects we observed on sleep processes by specifically deleting *Bmal1* in skeletal muscle ([@bib22]). Mice lacking BMAL1 in their skeletal muscle had significantly increased baseline NREM sleep amount, a result similar to whole-body *Bmal1* knockout mice ([Figure 3A--C](#fig3){ref-type="fig"}). Moreover, when muscle-specific knockouts were examined after 6 hr of forced wakefulness, recovery sleep was nearly half that of WT mice ([Figure 3D](#fig3){ref-type="fig"}). Forced wakefulness also increased SWA in these mice when compared to controls ([Figure 3D](#fig3){ref-type="fig"}). This effect on SWA suggests that these mice have higher sleep intensity than WTs during recovery from sleep loss. Together, these data support a role for skeletal muscle and *Bmal1* in regulating the ability to recover from sleep loss. Moreover, these data support the conclusion that *Bmal1* expression in skeletal muscle is both necessary and sufficient for the regulation of normal NREM sleep amount.10.7554/eLife.26557.007Figure 3.Knockout of *Bmal1* in skeletal muscle increases NREM sleep amount and confers resistance to sleep loss.Selective knockout of *Bmal1* in skeletal muscle significantly increased NREM sleep, but not REM sleep, when compared to the same animals prior to tamoxifen treatment (**A**, **B**; t~(10)~=2.52, p=0.036). Treatment of floxed mutant control animals with tamoxifen did not significantly alter NREM sleep or REM sleep (**C**). Following tamoxifen treatment, mice underwent 6 hr of sleep deprivation. Muscle knockout mice also had a significantly altered recovery response to this treatment. Significantly less NREM recovery sleep (t~(11)~=2.44, p=0.033) and increased NREM slow wave activity (t~(11)~=2.2, p=0.05) was observed in muscle knockout mice when compared to tamoxifen-treated floxed mutants (D). n = 6 per group; \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.007](10.7554/eLife.26557.007)10.7554/eLife.26557.008Figure 3---figure supplement 1.Slow wave activity in inducible muscle knockout mice and controls during undisturbed baseline sleep.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.008](10.7554/eLife.26557.008)

That many of the sleep phenotypes caused by whole-body BMAL1 deficiency are either rescued by muscle-specific *Bmal1* expression or recapitulated by muscle-specific *Bmal1* deletion suggest that sleep phenotypes in the *Bmal1* knockout mice are, in whole or in part, due to loss of BMAL1 in skeletal muscle. Thus, these results suggest an important role for skeletal muscle in sleep regulation, implying that *Bmal1*-dependent processes in skeletal muscle may be useful therapeutic targets for sleep disorders. In an effort to investigate the therapeutic potential of muscle *Bmal1*, we examined sleep architecture in wild type mice harboring either the brain or muscle-specific ([@bib4]) *Bmal1* transgene. In these mice, transgene expression is in addition to endogenous *Bmal1* expression. Neither baseline sleep nor SWA was significantly altered in brain overexpressed mice ([Figure 4B](#fig4){ref-type="fig"}). Baseline sleep amount was not significantly altered in muscle- overexpressed mice, however, baseline SWA was significantly reduced ([Figure 4A](#fig4){ref-type="fig"}), suggesting that overexpressing BMAL1 in the muscle renders mice resistant to sleep loss ([@bib11]). Furthermore, cholinergic neurons of the basal forebrain, which are important for recovery from sleep loss ([@bib16]), are more active in *Bmal1* muscle-overexpressed mice ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).10.7554/eLife.26557.009Figure 4.Overexpression of *Bmal1* in skeletal muscle confers resistance to sleep loss.24 hr electroencephalographic recordings were conducted in undisturbed mice overexpressing *Bmal1* in skeletal muscle (**A**) or brain (**B**). No differences in baseline sleep amount were found, however, NREM slow wave activity was significantly reduced in mice overexpressing *Bmal1* in skeletal muscle (**A**). Overexpression of *Bmal1* in skeletal muscle also significantly decreased the NREM-recovery response to one (24 hr) day of forced wakefulness by means of a slowly rotating wheel (**C, D**). It is not unusual for mice to obtain brief amounts of sleep (i.e. micro-sleep) during such an extended regimen of forced wakefulness. This sleep obtained during forced wakefulness was also significantly lower in mice overexpressing *Bmal1* (A, ANOVA main effect of genotype F~(1,\ 96)~=10.12, p=0.002, main effect of time F~(11,\ 96)~=4.1, p\<0.001; B, NREM sleep amount t~(8)~=1.85, p=0.047, NREM recovery sleep t~(8)~=1.9, p=0.039). NREM slow wave activity (a standard marker of sleep intensity) was consistently lower in *Bmal1* muscle-overexpressed mice throughout the 72 hr protocol (D, repeated-measures ANOVA F~(1,8)~=6.57, p=0.04). In contrast, during forced wakefulness waking slow-wave activity was significantly increased in *Bmal1* muscle-overexpressed mice (D, repeated-measures ANOVA main effect of genotype, F~(1,8)~=5.7, p=0.045). Grey bars indicate forced wakefulness, black bars indicate darkness (active period). Data presented as mean ± s.e.m, n = 16 muscle overexpression, n = 16 littermate controls (muscle), brain overexpression n = 8, littermate controls (brain) n = 11. \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.009](10.7554/eLife.26557.009)10.7554/eLife.26557.010Figure 4---figure supplement 1.Fos-immunoreactivity (IR) in densely cholinergic areas is increased in *Bmal1* muscle-overexpressed mice.Fos-IR in three brain areas known to be involved in sleep---wake regulation was assessed. Male mice were sacrificed at mid-day by CO~2~ inhalation in the presence (SD) or absence (Bsln) of 6 hr sleep deprivation. \*\*p\<0.05; wild-type n = 5; muscle overexpressed n = 6. Basal forebrain, F~1,16~=26.6, p\<0.001, univariate ANOVA; lateral habenula (Hb), F~1,16~=75.6, p\<0.001; pedunculopontine tegmentum (PPT), F~1,16~=31.0, p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.010](10.7554/eLife.26557.010)10.7554/eLife.26557.011Figure 4---figure supplement 2.Activity rhythms in *Bmal1* muscle-overexpressed mice are modestly increased when compared to wildtype mice.No differences were found in the circadian rhythm of wheel-running activity between either genotype \[Left panel\]. Overall locomotor activity measured with infrared sensors revealed increased activity of muscle-overexpressed mice at several time points (n = 7--8/genotype; Right panel). \*p\<0.05, repeated measures ANOVA \[one-way ANOVA, post-hoc\]; zeitgeber time 12 = activity onset; LD, light---dark cycle; DD, constant darkness.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.011](10.7554/eLife.26557.011)10.7554/eLife.26557.012Figure 4---figure supplement 3.*Bmal1* muscle-overexpressed mice do not have not altered levels of CLOCK:BMAL1-target genes in the brain or muscle.No significant differences in CLOCK:BMAL1-target gene expression between wildtype and muscle-overexpressed mice were found in the hypothalamus at either time point investigated (ZT5 and ZT17). As expected, *Bmal1* expression was significantly elevated in the muscle of muscle-overexpressed mice (32.4-fold increase at ZT5 vs. WT; F~1,22~=15.3, p=0.001, two-way ANOVA; 5.1-fold increase at ZT 17, p=0.003). \*\*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.26557.012](10.7554/eLife.26557.012)

To further investigate recovery from sleep loss, muscle-overexpressed mice were subjected to 24 hr of forced wakefulness by placing mice in a slowly rotating wheel (the 6 hr of forced wakefulness used previously is relatively mild). It is common for mice to exhibit some sleep during prolonged forced-wakefulness paradigms, however, *Bmal1* muscle-overexpressed mice were awake more than WT littermates during these 24 hr of forced wakefulness ([Figure 4C](#fig4){ref-type="fig"}). Similar to baseline, *Bmal1* muscle-overexpressed mice also had less NREM recovery after forced wakefulness (recovery = sleep gained in recovery/sleep lost during forced wakefulness; [Figure 4C](#fig4){ref-type="fig"}) and reduced SWA throughout the 72 hr protocol compared to WT mice ([Figure 4D](#fig4){ref-type="fig"}), despite sleeping less. In addition, waking SWA (a measure of accumulating sleep pressure during extensive durations of sleep loss; [@bib8]) rose more rapidly and was consistently higher than in WT mice during 24 hr of forced wakefulness ([Figure 4D](#fig4){ref-type="fig"}). Combined, these results demonstrate that overexpressing *Bmal1* in the skeletal muscle renders mice less sensitive to the effects of sleep loss, portending muscle as a potential therapeutic target for sleep loss.

How might peripheral tissues such as muscle influence sleep? The rapidly emerging area of muscle-derived factors on systemic health provides a potential model for our findings. In particular, there are several examples of muscle-derived factors that alter brain processes. Notably, overexpression of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1α, gene symbol: *Ppargc1a*) selectively in mouse skeletal muscle reduces the depressive phenotypes induced by stress by preventing plasma kynurenine from reaching the brain ([@bib1]). Furthermore, PGC-1α activation stimulates release of the muscle-derived peptide irisin into circulation ([@bib3]). Plasma irisin, in turn, induces BDNF expression in the hippocampus ([@bib33]). Indeed, *PGC-1α* expression is rhythmic in skeletal muscle ([@bib20]) raising the possibility that alterations in *Bmal1* expresion/function may alter rhythmic *PGC1α* expression through a change in clock function. However, the studies presented here are not sufficient to determine if the sleep effects of loss/gain of *Bmal1* function in skeletal muscle are via core clock or non-clock mechanisms. Furthermore, whole body deletions of other circadian factors such as *Per1* and *Per2* ([@bib28]), and *Cry1* and *Cry2* ([@bib32]), do not have similar effects on sleep. Other potential contributors could be related to changes in muscle metabolism as *Bmal1* metabolic phenotypes have been reported in both muscle mouse-lines used here ([@bib14]; [@bib4]).

Recent studies have highlighted that sleep disruptions in humans are associated with peripheral circadian desynchrony ([@bib9]; [@bib27]). The current study demonstrates that manipulating levels of the circadian transcription factor *Bmal1* specifically in skeletal muscle alters sleep. Moreover, a majority of these effects of *Bmal1* on sleep are not dependent on circadian timing in the brain---dependence on circadian timing in the skeletal muscle remains a possibility. Although it has been established that sleep is important for skeletal muscle function (for a review, see [@bib10]), these investigations are the first to implicate molecular processes within skeletal muscle in signaling sleep regulatory mechanisms in the brain. Studies in our lab are currently underway to determine the nature of the pathway skeletal muscle uses to signal sleep regulatory mechanisms in the brain.

Materials and methods {#s2}
=====================

Animals {#s2-1}
-------

All mice in the brain lines and muscle rescued/overexpressed lines were maintained on a 12-hr light:12-hr dark schedule throughout the study. Food and water were available *ad libitum*, and animals (10--12 w of age) were individually housed for at least 2 weeks prior to experimental use. All protocols and procedures were approved by the Morehouse School of Medicine Institutional Animal Care and Use Committee.

*Bmal1* brain-rescued and brain overexpressed mice used the tetracycline transactivator (tTA) system, which requires two transgenes for expression of the target gene *Bmal1* (previously reported in [@bib25]; RRID:[MGI:3714773](https://scicrunch.org/resolver/MGI:3714773)). The promoter sequence of the secretogranin II gene (*Scg2),* which is expressed exclusively in the brain, drives expression of the tetracycline transactivator (*tTA*). The tTA protein binds to the tetracycline operator (*tetO*) sequence and drives expression of *Bmal1* cDNA. The double transgenic mice were crossed onto a *Bmal1* knockout background (RRID:[IMSR_JAX:009100](https://scicrunch.org/resolver/IMSR_JAX:009100)) to create brain-rescued mice and were crossed onto a *Bmal1* WT background to create brain overexpressed mice. Breeding was conducted in-house and genotypes were recorded as they became available from breeding. For rescue lines, animals from approximately 20--25 litters comprised the entire dataset. WT littermates obtained from these litters were kept separate for comparisons in each line. KO mice were offspring from independent crosses of heterozygous *Bmal1* KO's.

In situ hybridization studies demonstrate that *Scg2* mRNA is found throughout the brain with the higher expression in the hypothalamus and peak expression in the SCN. Moderate expression of *Scg2* is detected in midbrain and hypothalamic nuclei of the ascending arousal system and in the sleep promoting ventrolateral preoptic area ([@bib19]). The mice used in the present study, constructed with a 9.8 kb promoter region of *Scg2*, were characterized previously ([@bib15]). Briefly, *Scg2::tTA* mice express the *tTA* transcript broadly in the brain and is enriched in the SCN, when assessed by both an oligo to the *tTA* transcript and by crosses with *tetO*-promotor-linked reporter lines ([@bib15]). Furthermore, in situ hybridization in *Scg2::tTA X tetO::Bmal1-HA* and *tetO::Bmal1-*HA mice demonstrate that *Bmal1* expression is under strict control of the tetracycline transactivator: Hemagglutinin (HA)-tag expression is only detectable in the double transgenic mouse. Both *Bmal1* mRNA and protein are constitutively expressed in the brain of brain-rescued mice. ([@bib25]). Brain specificity has been demonstrated by western blot which shows an absence of HA-staining in both the muscle and liver of double transgenic mice ([@bib25]).

*Bmal1* muscle-rescued and muscle-overexpressed mice were generated with the use of a DNA construct consisting of human α-actin-1 promoter sequence positioned upstream of *Bmal1* (RRID:[MGI:3714769](https://scicrunch.org/resolver/MGI:3714769); [@bib25]). The transgenic mice were crossed onto a *Bmal1* knockout background to create muscle-rescued mice, and also crossed onto a *Bmal1* WT background to create brain-overexpressed mice.

The skeletal muscle-specific Cre-recombinase mouse (*Acta1-cre/Esr1^\*^*, RRID:[IMSR_JAX:025750](https://scicrunch.org/resolver/IMSR_JAX:025750)) was generated in house ([@bib22]). Breeding with the floxed *Bmal1* mouse (*Bmal1^lox/lox^*, The Jackson Laboratory, RRID:[IMSR_JAX:007668](https://scicrunch.org/resolver/IMSR_JAX:007668); [@bib30]) generated the inducible muscle knockout mouse. These offspring (*Bmal1^lox/lox^; Acta1-cre/Esr1^\*^*) allow selective deletion of the bHLH domain of *Bmal1* in skeletal muscle upon tamoxifen administration.

The *Acta1* promoter used for both mouse lines (muscle rescued/overexpressed and muscle KO) is a 2.2 kb sequence directly upstream from the human skeletal actin (*Acta1* gene) translational start site. Proper developmental and tissue-specific expression has been verified previously using an *Acta1::CAT* mouse line. These findings included a demonstrated lack of expression in the brain ([@bib5]). Specific Cre-dependent excision of a loxP-flanked gene in mouse striated muscle fiber was also demonstrated in mice expressing Cre recombinase under the control of this same promoter ([@bib26]). Transgene expression in the inducible muscle knockout mice (*Acta1-cre/Esr1\**) used here is constitutive and was not detectable in brain by western blot ([@bib23]). A lack transgene expression in the brain has also been demonstrated for the *Acta1::Bmal1-HA* line ([@bib25]). We verified this finding by western blotting an entire brain hemisphere or gastrocnemeous muscle in mice bred at our facility ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). HA-tag was detected in skeletal muscle, but not brain.

Surgery {#s2-2}
-------

EEG and EMG electrodes were implanted in anesthetized mice. A prefabricated head mount (Pinnacle Technologies, KS) was used to position three stainless-steel epidural screw electrodes. The first electrode (frontal---located over the frontal cortex) was placed 1.5 mm anterior to bregma and 1.5 mm lateral to the central suture, whereas the second two electrodes (interparietal---located over the visual cortex and common reference) were placed 2.5 mm posterior to bregma and 1.5 mm on either side of the central suture. The resulting two leads (frontal-interparietal and interparietal-interparietal) were referenced contralaterally. A fourth screw served as a ground. Electrical continuity between the screw electrode and head mount was aided by silver epoxy. EMG activity was monitored using stainless-steel Teflon-coated wires that were inserted bilaterally into the nuchal muscle. The head mount (integrated 2 × 3 pin grid array) was secured to the skull with dental acrylic. Mice were allowed to recover for at least 14 days before sleep recording.

EEG/EMG Recordings {#s2-3}
------------------

One week after surgery, mice were moved to the sleep-recording chamber and connected to a lightweight tether attached to a low-resistance commutator mounted over the cage (Pinnacle Technologies). This enabled complete freedom of movement throughout the cage. Except for the recording tether, conditions in the recording chamber were identical to those in the home cage. Breeding was conducted in-house, and genotypes were recorded as they became available from breeding. Recordings from approximately 20--25 litters makup the dataset. All wildtype and KO littermates resulting from a litter, up to a maximum of 50%, were recorded with tissue-specific knockout/rescue mice. Mice were allowed a minimum of 7 additional days to acclimate to the tether and recording chamber. Recording of EEG and EMG waveforms began at zeitgeber time (ZT) 0 (light onset). Data acquisition was performed on a personal computer running Sirenia Acquisition software (Pinnacle Technologies), a software system designed specifically for polysomnographic recording in rodents. EEG signals were low-pass filtered with a 40 Hz cutoff and collected continuously at a sampling rate of 400 Hz. After collection, all waveforms were classified by a trained observer (using both EEG leads and EMG) as wake (low-voltage, high-frequency EEG; high-amplitude EMG), NREM sleep (high-voltage, mixed-frequency EEG; low- amplitude EMG) or rapid eye movement (REM) sleep (low-voltage EEG with a predominance of theta activity \[6--10 Hz\]; very low amplitude EMG). EEG epochs determined to have artifact (interference caused by scratching, movement, eating, or drinking) were excluded from analysis. Recordings where artifact comprised more than 5% of total recording time were excluded from analysis. Analysis of NREM delta power and NREM spectral distribution was accomplished by applying a fast Fourier transformation to raw EEG waveforms. Only epochs classified as NREM sleep were included in this analysis. Delta power was measured as spectral power in the 0.5 to 4 Hz frequency range and expressed as a percentage of total spectral power in the EEG signal (0.5--100 Hz) during that time period.

Forced wakefulness {#s2-4}
------------------

Homeostatic challenge: Six-hour forced wakefulness was conducted in all mouse lines ([Figure 2](#fig2){ref-type="fig"}). Following a 24 hr baseline recording, mice were sleep deprived during the first 6 hr of the light phase (ZT 0--6) by gentle handling (introduction of novel objects into the cage, tapping on the cage and when necessary delicate touching) and allowed an18-hr recovery opportunity (ZT 6--0).

Twenty-four-hour forced wakefulness: Following a 24 hr baseline recording, *Bmal1* muscle-overexpressed lines and WT littermates were moved to a slowly rotating wheel (nine inches in diameter; 1 rpm) adjacent to the recording cage ([Figure 3](#fig3){ref-type="fig"}). Mice were confined to this wheel for 24 hr beginning at ZT 0 (lights on) during which time they had free access to food and water. Following sleep deprivation, animals were returned to the baseline recording cage and EEG acquisition was continued for a 24 hr recovery opportunity.

Fos- and choline acetyltransferase (ChAT) immunoreactivity (IR) {#s2-5}
---------------------------------------------------------------

Mice were sacrificed by CO~2~ inhalation at ZT 6 (ZT0 represented lights-on under LD) after 6 hr of forced wakefulness. Brains were immersion-fixed in 4% paraformaldehyde for 24 hr then sunk in 30% sucrose (24 hr at 4°C). Cryostat sections (40µm-thick) were incubated with a rabbit polyclonal IgG antibody (c-fos; Santa Cruz Biotechnology, Santa Cruz, CA; chicken polyclonal IgY antibody \[ChAT\]; Novus Biologicals, Littleton, CO) and immunoreactivity was visualized using Vectastain Elite ABC kit with 3,3-diaminobenzidine tetrahydrochloride (DAB) as chromagen (Vector Labs, Burlingame, CA). Sections were mounted with permount, and Fos expression was quantified using ImageJ (National Institutes of Health, Bethesda, MD). Counts of immunostained nuclei were undertaken in the mid-to-posterior region of each brain site.

Quantitative PCR {#s2-6}
----------------

Methods were described previously ([@bib23]). Briefly, brain (hypothalamic) and skeletal muscle (gastrocnemius) tissues were collected from mice sacrificed at ZT5 and ZT17 (ZT12 was lights-off under a 12 hr: 12 hr light:dark cycle); these are the mid-points of peak and trough *Bmal1* gene expression in skeletal muscle ([@bib21]). Total RNA was extracted from frozen brain and skeletal muscle using Trizol (Invitrogen, Carlsbad, CA) and diluted to 0.1 mg/ml. Samples were converted from RNA to cDNA with Applied Biosystems RT-PCR kit reagents according to the manufacturer's instruction. Real-time PCR assays were performed using the comparative amplification detection threshold of target gene expression (CT) method. mRNA levels detected with SYBR Green (Bio-Rad; Hercules, CA) were measured by determining the cycle number at which CT was reached. In each sample, CT was normalized to *Gapdh* expression (ΔCT) performed on the same plate. Normalized gene expression (ΔΔCT) for each gene with respect to genotype and time point was computed with Bio-Rad CFX Manager.

Western blotting {#s2-7}
----------------

Brain hemispheres were homogenized in a microfuge tube using a pellet pestle in 700 ul lysis buffer (20 mM Hepes pH 7.6, 400 mM NaCl, 1 mM EDTA, 5 mM NaF, 0.3% Triton-X 100, 5% glycerol, 1 mM DTT, 250 nM PMSF, and complete protease inhibitor mix (Sigma), and tumbled at 4C overnight prior to quantification and loading on the gel. Muscle proteins were extracted similarly, except 300 µl to lysis buffer was used, and the lysis buffer contained 1% Triton X-100% and 10% glycerol. Protein concentrations were determined using a BCA assay kit (Pierce), and separated on an Any-kDa minigel (BioRad). Western blot was performed with anti-HA-HRP conjugated monoclonal antibody (Roche) and anti-Gapdh (Santa Cruz).

Behavioral phenotyping {#s2-8}
----------------------

### Wheel running {#s2-8-1}

Male mice were provided with continuous access to running wheels interfaced to a ClockLab data acquisition system (Coulbourn Instuments, Whitehall, PA) for two weeks under LD followed by 2 weeks under constant darkness (DD; n = 8/genotype). Data were collected in 10 min bins. Nighttime activity onset (designated as zeitgeber time \[ZT\] 12 under LD and circadian time \[CT\] 12 under DD) was defined by the initial 10 min period that: (1) exceeded 10% of the maximum activity for the day, (2) was preceded by at least 4 hr of inactivity, and (3) was followed by at least 60 min of sustained activity. Nighttime activity offset was defined as the final period of nighttime activity that: (1) was preceded by at least 60 min of sustained activity and (2) was followed by at least 4 hr of inactivity. Alpha (measured in h) represented the time between nighttime activity onset and offset. Rhythm period was determined from extrapolation of the least squares line through activity onsets on days 3--14 under LD and DD. The duration (bout) and intensity (count) of wheel running under LD and DD were also measured.

### Beam breaks {#s2-8-2}

A SmartHomeCage data acquisition system (AfaSci, Redwood City, CA) equipped with a multi-layer 3D array of infrared sensors was placed around the home cages of male mice (n = 7--8/genotype) to measure gross and fine motor movements under LD (following entrainment) and DD (third full 24 hr period, CT time derived from each individual animal's rhythm period). Behavioral parameters included the number of spontaneous movements (counts), % activity in 1 hr blocks, distance travelled in home cage, and minutes of gross (ambulatory) and fine (grooming) motor movements.

Statistics {#s2-9}
----------

Sleep data were analyzed using one-way analysis of variance (ANOVA), repeated-measures ANOVA or Student's *t*. Significance was defined as p≤0.05. *Post hoc* analysis was conducted using Tukey's HSD method or student *t*-test where indicated. Tukey's HSD method uses the studentized range statistic and maintains family-wise error-rate at 0.05. An appropriate sample size of 5 was predicted with Type I error rate of 0.05 and Type II error rate of 0.2. Standard deviation and mean difference were estimated as 46.4 and 100 min, respectively, based on the existing literature ([@bib18]) and previous studies in our lab. Sample sizes (biological replicates) for each experiment are indicated in the figure legends.

Supplementary materials {#s2-10}
-----------------------

### Overexpression of *Bmal1* in the skeletal muscle increases Fos-IR in cholinergic neurons {#s2-10-1}

The finding that *Bmal1* muscle overexpression altered brain EEG led us to investigate whether the manipulation had other influences on brain phenotypes that are related to sleep-wake processes. Therefore, we determined the effects of *Bmal1* muscle overexpression on neuronal activation in sleep regulatory regions. FOS-immunoreactivity (IR) was measured in the following brain areas: (1) forebrain (nucleus accumbens \[NAc/s\], basal forebrain \[BF\], ventral pallidum \[VP\]); (2) hypothalamus (ventral lateral \[VLPO\] and medial preoptic \[MPOA\] areas, suprachiasmatic nucleus \[SCN\]); (3) thalamus (lateral habenula \[LAh\]); and (4) hindbrain (ventral \[VTA\], pedunculopontine \[PPT\], and laterodorsal \[LDT\] tegmental areas (S1). Brains were collected at midday under basal (undisturbed) conditions or immediately after a 6 hr of sleep deprivation.

FOS-IR was increased in the forebrain, midbrain, and hindbrain of *Bmal1* muscle-overexpressed mice relative to WTs (BF: F~1,16~=26.6; p\<0.001, univariate ANOVA; Hb: F~1,16~=75.6; p\<0.001; PPT: F~1,16~=31.0; p\<0.001; LDT: F~1,16~=34.5; p\<0.001). There were also significant increases in FOS-IR in the forebrain, midbrain and hindbrain (NAc: F~1,16~=15.5; p=0.001; BF: F~1,16~=6.8; p=0.01; PPT: F~1,16~=12.6; p=0.004; Hb: F~1,16~=26.6; p\<0.001; MpOA; F~1,16~=15.6; p=0.001) of sleep-deprived mice. Most notably, there were no main effects for genotype or treatment in the SCN. This observation indicates that disrupted circadian timing is not responsible for sleep phenotypes in *Bmal1* muscle-overexpressed mice.

Coincidentally, the brain areas that had increases in FOS-IR in response to *Bmal1* muscle overexpression---the basal forebrain, lateral habenula, and pedunculopontine tegmentum---are known to be arousal promoting and have extensive cholinergic tone. We double-labeled with ChAT (enzyme necessary for acetylcholine synthesis) to determine if cholinergic neurons are FOS-positive. Our findings indicate that increases in Fos-IR of *Bmal1* muscle-overexpressed mice occurred in cholinergic neurons (BF: F~1,20~=5.6; p=0.02; Hb: F~1,20~=14.8; p=0.002; PPT: F~1,20~=13.5; p=0.003; S1).

### Overexpression of *Bmal1* in the skeletal muscle does not cause circadian impairments in wheel running {#s2-10-2}

The patterns of circadian wheel-running activity have been reported in the majority of mouse models reported here ([@bib25]; [@bib32]); however, this wheel-running activity is not available for *Bmal1* muscle-overexpressed mice. Therefore, we investigated behavioral circadian rhythms in *Bmal1* muscle-overexpressed mice and WT littermates.

*Bmal1* muscle-overexpressed mice entrained to LD and had a nighttime activity onset of 12.2 ± 8.4 min after lights-off. WTs entrained to LD with a nighttime activity onset of 5.4 ± 3.4 min after lights-off (*onset*: F~1,14~=0.77; p=0.39, one-way ANOVA). The length of the nighttime activity period averaged 11.0 ± 1.1 hr for *Bmal1* muscle- overexpressed mice and 10.7 ± 0.6 hr for WTs (F~1,14~=0.06; p=0.81, one-way ANOVA). The average duration of a wheel running bout was 176.2 ± 52.3 min for *Bmal1* muscle-overexpressed mice and 131.6 ± 19.4 min of wheel running for WTs (*duration:* F~1,14~=1.3; p=0.27; *intensity*: F~1,14~=0.49; p=0.41, one-way ANOVA). Overexpression of *Bmal1* in the skeletal muscle did not change the endogenous rhythm of wheel running. Rhythm period for *Bmal1* muscle-overexpressed mice averaged 23.7 ± 0.1 hr compared with 23.8 ± 0.2 hr for WTs (F~1,13~=0.90; p=0.36, one-way ANOVA). The duration of the subjective night was also unaffected in *Bmal1* muscle overexpressed-mice compared with WTs (10.4 ± 1.1 hr vs. 9.1 ± 0.9 hr, respectively; F~1,13~=0.18; p=0.68, one-way ANOVA).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*Bmal1* function in skeletal muscle regulates sleep\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, J Ptáček (Reviewer \#1), is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: John B Hogenesch (Reviewer \#2) and Katja A Lamia (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In Ehlers et al., the authors study the role of *Bmal1* in regulating sleep and recovery from sleep debt. Earlier, it was noted that *Bmal1* null mice, like most circadian clock null mice, have sleep abnormalities including increased total sleep and NREM sleep intensity and reduced recovery to sleep loss. The authors rescued *Bmal1* function in the brain with a *Scg2::tTA* system, but while this rescued circadian function, surprisingly, it had no effect on sleep. Next, they restored *Bmal1* function to skeletal muscle using a *Acta1* driven *Bmal1* construct in a constitutive fashion and showed that *Bmal1* in muscle is sufficient to restore normal NREM sleep amount. They went on to show similar results for recovery from sleep deprivation. To demonstrate the necessity of *Bmal1* function in skeletal muscle, they generated muscle-specific *Bmal1* knockout mice and showed sleep phenotypes consistent with muscle *Bmal1* function being important for sleep. They went on to overexpress *Bmal1* in skeletal muscle, sleep deprived animals, and showed further resistance to sleep deprivation, demonstrating that *Bmal1* is gene dose limiting in mediating resistance sleep deprivation.

The findings are supported by the data and will be of interest to a broad scientific audience. The paper could be strengthened by more thorough description and discussion of their data in relation to other studies. Some of the conclusions should be clarified with respect to possible underlying direct or indirect mechanisms and in relation to other findings. Finally, some of the data presentation should be clarified.

Despite these technical concerns, I feel this is interesting and worth reporting but that it will be necessary for the authors to acknowledge potential problems noted above to be sufficiently conservative in interpretation.

Essential revisions:

This is a very interesting idea and the data is strongly suggestive. It is clear that exercise improves subsequent sleep quality and it is interesting to speculate that this might result from some humoral factor released from muscle. The main concern is that the authors are not sufficiently careful in the interpretation of their findings. They used *Scg2-Bmal1* to rescue the brain expression. Obviously the expression of *Scg2* (levels, cell types, etc.) are somewhat different from that of endogenous *Bmal1*, although the circadian rhythm phenotype could be rescued. However, little is known about sleep regulation and all of the brain regions that might be involve. So even if *Scg2-Bmal1* could not rescue the *Bmal1* KO sleep phenotype, it is overstated that brain-specific expression of *Bmal1* could not rescue the sleep phenotype. Perhaps the relevant brain region (and specific cell types) do not have sufficiently high expression of the exogenous *Bmal1* to rescue the phenotype.

Similarly, they used *Acta1-Bmal1* as the model of muscle specific rescue. Although *Bmal1* in this model is supposed to be restricted, it is impossible to exclude the expression of this promoter in some specific area or cell types in the brain that might be critically relevant for rescue of the phenotype.

1\) The authors speculate that a *Bmal1* target gene involved in regulation of a circulatory factor mediates the sleep effects seen in muscle perturbation of *Bmal1* function. This seems highly likely. Does this imply it\'s likely to be a circadian-clock regulated gene or a non-circadian target of *Bmal1*? This point may merit discussion.

2\) The promoters used here should be described more clearly. E.g. Where is *Scg2* expressed in the brain, broadly or discretely? Constitutively or in a circadian fashion? Similarly, while the *Acta1* promoter used is supposed to be quite clean, was this verified by ICC or immunoblot? Expression of transgenes can \'leak\' over time.

3\) The kyurenine hypothesis is interesting, but as far as I can tell, the aminotransferase thought to be responsible, Ccbl1, is more likely to be a Ror (driven by Pgc1a) than *Bmal1* target. (Ccbl1 also shares phase with *Bmal1* in liver, opposite from canonical *Bmal1* targets such as Dbp and Nr1d1.)

5\) There seems to be a correlation between reduced locomotor activity, altered temporal organization of activity, and reduced NREM sleep and altered temporal organization of NREM sleep patterns. Could altered levels of physical activity contribute to differences in sleep structure?

6\) The authors should more carefully describe the phenotypes to clearly state that the diurnal patterns of sleep are not restored by rescuing *Bmal1* expression in skeletal muscle. Perhaps [Figure 1](#fig1){ref-type="fig"} could include quantification of the light and dark phase NREM and REM sleep. This is reminiscent of the earlier report showing that in a *Bmal1*KO background rescue of *Bmal1* in brain restored diurnal activity patterns but not the overall amount of activity while rescue in muscle restored levels of activity but not consolidation (McDearmon et al., 2006). That study also showed that rescuing *Bmal1* in muscle restored body weight of *Bmal1* KO mice. Could there be an overarching metabolic change that contributes to both body weight restoration and sleep propensities?

7\) The statement in the Abstract that \"\[...\] most of these phenotypes could be reproduced or rescued by knocking out or restoring BMAL1 exclusively in the skeletal muscle \[...\]\" is too strong. This should be qualified with a statement about rescuing the overall levels but not the altered timing of sleep.

8\) More detail should be provided with respect to the tissue specificity of the mouse lines used. The *Scg2::tTa* is limited to the SCN and several other regions; this should be clarified to avoid the implication that rescue of *Bmal1* expression throughout the brain has no effect on sleep. Is it known that *Acta1-cre/Esr1\** line does not express Cre in brain regions that are important for modulating sleep?

9\) In [Figure 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, \"wildtype\" and \"knockout\" data are presented with both the muscle-rescued line and the brain-rescued line but it is unclear whether these are the same data from an independent colony or whether the \"knockout\" mice are littermates of the brain-rescued and muscle-rescued animals.

10\) In [Figure 2](#fig2){ref-type="fig"}, it is unclear what exactly is shown in panels A and B. It seems to be a calculation based on comparison to the corresponding interval during undisturbed sleep for the same genotype or the same animal but could this artificially alter the value since the undisturbed diurnal sleep patterns are quite different for the different genotypes? It might be better to present the \"baseline\" and the \"recovery\" data together to get a clear picture of how the genetic changes affect recovery from sleep deprivation, as in Laposky et al., 2005 demonstrating effects of ubiquitous *Bmal1* loss on sleep.

10.7554/eLife.26557.014

Author response

*Essential revisions:*

*\[...\] 1) The authors speculate that a Bmal1 target gene involved in regulation of a circulatory factor mediates the sleep effects seen in muscle perturbation of Bmal1 function. This seems highly likely. Does this imply it\'s likely to be a circadian-clock regulated gene or a non-circadian target of Bmal1? This point may merit discussion.*

We appreciate the reviewer's question regarding potential clock vs. non-clock mechanisms. We have attempted to address this in our discussion of potential mechanisms in paragraphs 8 and 9. In our opinion the current data do not provide sufficient evidence and determining the involvement of the clock will depend on identification of the mechanistic link between muscle and brain. Therefore, we have integrated this discussion with our discussion of muscle-derived factors. A complete description of these changes can be found in 3) below.

It is important to point out that whole-body deletions of other canonical circadian clock genes do not have similar effects on sleep. The following sentence was added to paragraph 8 of the manuscript: "Furthermore, whole body deletions of other circadian factors such as Per1 and Per2 (Shiromani et al., 2004), and Cry1 and Cry2 (Wisor et al., 2008), do not have similar effects on sleep."-

*2) The promoters used here should be described more clearly. E.g. Where is Scg2 expressed in the brain, broadly or discretely? Constitutively or in a circadian fashion? Similarly, while the Acta1 promoter used is supposed to be quite clean, was this verified by ICC or immunoblot? Expression of transgenes can \'leak\' over time.*

We have included [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} to demonstrate the appropriate tissue-specific expression of the transgene in the *Acta1::Bmal1-HA* line. In addition, the following text has been added to the Material and methods section:*"In situ* hybridization studies demonstrate that *Scg2* mRNA is found throughout the brain with the higher expression in the hypothalamus and peak expression in the SCN. \[...\] Brain specificity has been demonstrated by western blot which shows an absence of HA-staining in both the muscle and liver of double transgenic mice (McDearmon, 2006*)."*

"The *Acta1* promoter used for both mouse lines (muscle rescued/overexpressed and muscle KO) is a 2.2 kb sequence directly upstream from the human skeletal actin (*Acta1* gene) translational start site. \[...\] We verified this finding by western blotting an entire brain hemisphere or gastrocnemeous muscle in mice bred at our facility ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). HA-tag was detected in skeletal muscle, but not brain."

*3) The kyurenine hypothesis is interesting, but as far as I can tell, the aminotransferase thought to be responsible, Ccbl1, is more likely to be a Ror (driven by Pgc1a) than Bmal1 target. (Ccbl1 also shares phase with Bmal1 in liver, opposite from canonical Bmal1 targets such as Dbp and Nr1d1.)*

Thank you for pointing this out. We have altered the text to clarify our hypothesis and address comment 1). The text in paragraph 8 and 9 now reads: "How might peripheral tissues such as muscle influence sleep? \[...\] Furthermore, whole body deletions of other circadian factors such as *Per1* and *Per2* (Shiromani et al., 2004), and *Cry1* and *Cry2* (Wisor et al., 2008), do not have similar effects on sleep."

*5) There seems to be a correlation between reduced locomotor activity, altered temporal organization of activity, and reduced NREM sleep and altered temporal organization of NREM sleep patterns. Could altered levels of physical activity contribute to differences in sleep structure?*

A correlation between decreased activity and altered temporal organization is seen in whole-body *Bmal1* KO's (Pendergast et al., 2008) and WT levels of activity are associated with WT-like sleep structure in the muscle-KO line (Harfmann et al., 2016). However, the patterns observed in the rescue lines are not consistent with this hypothesis. Locomotor activity remains low in brain-rescued mice and sleep structure is partially restored, whereas activity levels are partially restored in the muscle-rescued mice without a restoration of sleep architecture (McDearmon et al., 2006). Based on these data, it still isn't clear if differences in physical activity contributes to differences in sleep architecture.

*6) The authors should more carefully describe the phenotypes to clearly state that the diurnal patterns of sleep are not restored by rescuing Bmal1 expression in skeletal muscle. Perhaps [Figure 1](#fig1){ref-type="fig"} could include quantification of the light and dark phase NREM and REM sleep. This is reminiscent of the earlier report showing that in a Bmal1KO background rescue of Bmal1 in brain restored diurnal activity patterns but not the overall amount of activity while rescue in muscle restored levels of activity but not consolidation (McDearmon et al., 2006). That study also showed that rescuing Bmal1 in muscle restored body weight of Bmal1 KO mice. Could there be an overarching metabolic change that contributes to both body weight restoration and sleep propensities?*

We have altered paragraph 3 to address this first issue. The text now reads: "To begin this investigation of other tissues we chose mice harboring a transgene that restores *Bmal1* specifically in skeletal muscle, but does not restore circadian behavior (i.e., muscle rescued; *Acta1::Bmal1-HA*)."

"These experiments demonstrate that restoring *Bmal1* in the skeletal muscle of otherwise *Bmal1*-deficient mice is sufficient to restore normal NREM sleep amount, independently of *Bmal1* expression in the brain. The diurnal rhythm in sleep amount, however, is not restored ([Figure 1A](#fig1){ref-type="fig"})."

We have begun to address the issue of metabolic changes in our recent publication using muscle-overexpressed mice (Brager et al., 2017). We found no baseline differences in: body composition, respiratory exchange ratio, energy expenditure, total activity counts, and ex vivo insulin sensitivity in skeletal muscle, between muscle-overexpressed and WT mice. We did find that muscle-overexpressed mice had lower energy expenditure during treadmill running and reduced insulin sensitivity following sleep deprivation (Brager et al., 2017). This indicates that there are few metabolic changes in the muscle-overexpressed mice, a line that exhibits significant differences in SWA; however, differences in body composition and glucose tolerance were recently reported in muscle KO mice (Harfmann et al., 2016) and this line displayed increased sleep amount and SWA. Thus, it is possible that metabolic phenotypes contribute to the sleep phenotypes described here.

We have added the following to paragraphs 8 to address this: "Other potential contributors could be related to changes in muscle metabolism as *Bmal1* metabolic phenotypes have been reported in both muscle mouse-lines used here (Harfmann et al., 2016; Brager et al., 2017)."

*7) The statement in the Abstract that \"\[...\] most of these phenotypes could be reproduced or rescued by knocking out or restoring* BMAL1 *exclusively in the skeletal muscle \[...\]\" is too strong. This should be qualified with a statement about rescuing the overall levels but not the altered timing of sleep.*

We have rewritten this sentence in the Abstract: "Surprisingly, most sleep-amount, but not sleep-timing, phenotypes could be reproduced or rescued by knocking out or restoring BMAL1 exclusively in skeletal muscle, respectively."

*8) More detail should be provided with respect to the tissue specificity of the mouse lines used. The Scg2::tTa is limited to the SCN and several other regions; this should be clarified to avoid the implication that rescue of Bmal1 expression throughout the brain has no effect on sleep. Is it known that Acta1-cre/Esr1\* line does not express Cre in brain regions that are important for modulating sleep?*

The transgene expression-patterns exhibited in these lines is addressed in item 2).

*9) In [Figure 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, \"wildtype\" and \"knockout\" data are presented with both the muscle-rescued line and the brain-rescued line but it is unclear whether these are the same data from an independent colony or whether the \"knockout\" mice are littermates of the brain-rescued and muscle-rescued animals.*

We have added the following text to the Material and methods to clarify: "For rescue lines, animals from approximately 20-25 litters comprised the entire dataset. WT littermates obtained from these litters were kept separate for comparisons in each line. KO mice were offspring from independent crosses of heterozygous *Bmal1* KO's".

*10) In [Figure 2](#fig2){ref-type="fig"}, it is unclear what exactly is shown in panels A and B. It seems to be a calculation based on comparison to the corresponding interval during undisturbed sleep for the same genotype or the same animal but could this artificially alter the value since the undisturbed diurnal sleep patterns are quite different for the different genotypes? It might be better to present the \"baseline\" and the \"recovery\" data together to get a clear picture of how the genetic changes affect recovery from sleep deprivation, as in Laposky et al., 2005 demonstrating effects of ubiquitous Bmal1 loss on sleep.*

A major problem with interpreting the recovery response to a homeostatic challenge is controlling for the amount of sleep lost. This is especially true when comparing different strains where the amount of sleep lost during sleep deprivation can be different. To control for these differences, normalizing for the amount of lost sleep (by expressing sleep recovered as a percentage of sleep lost) is a standard practice in the sleep field. However, the pattern of sleep recovery does differ between genotypes and we agree that presenting the recovery day, as requested, will allow visualization of these differences. We have presented the data in both formats, the graphs requested are now included in the [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.
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